{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:07:19Z","timestamp":1759939639186,"version":"3.37.3"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Health Service"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003921","name":"Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"name":"George Drexler Foundation"},{"name":"BTCure EU","award":["115142\u20132"],"award-info":[{"award-number":["115142\u20132"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. TNF inhibitor (TNFi) drugs are recommended for patients not responding to NSAIDs; however, there is a significant need for biomarkers of response. IFN-regulated genes (IRGs) and other cytokines\/chemokines are linked to autoimmune diseases and have been associated with treatment response. Our objective was to explore whether IRGs and cytokines\/chemokines can be associated with response to TNFiagents in AS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Peripheral blood mononuclear cells were obtained from 26 AS patients who were to receive a TNFi (I, n\u2009=\u200915) or placebo (P, n\u2009=\u200911) at week 0 and week 22. Response (R)\/non-response (NR) was defined as reduction in ASDAS\u2009\u2265\u20091.2 points or reduction in sacroiliac\/vertebral MRI lesions. The expression of 96 genes was quantified using TaqMan assays. Finally, ELISA was used to measure IL-6 in serum samples from another 38 AS patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis of gene expression in 26 baseline samples segregated patients into four groups defined by a signature of 15 genes (mainly IRGs). ASDAS response was associated with one group independently of treatment received. We then analysed response to the TNFi (n\u2009=\u200915) and identified a 12-gene signature associated with MRI response. A third IRG signature was also associated with a reduction in IRGs expression post-TNFi samples (n\u2009=\u200910 pairs). Finally, decreased circulating IL-6 was associated with BASDAI-R.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This pilot study suggests an association between IRG expression and response to TNFi in AS. These findings require validation in a larger cohort in order to construct predictive algorithms for patient stratification.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa817","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T03:26:55Z","timestamp":1605842815000},"page":"3607-3616","source":"Crossref","is-referenced-by-count":6,"title":["Interferon-related gene expression in response to TNF inhibitor treatment in ankylosing spondylitis patients: a pilot study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-2621","authenticated-orcid":false,"given":"Stephanie R","family":"Harrison","sequence":"first","affiliation":[{"name":"University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata N","family":"Burska","sequence":"additional","affiliation":[{"name":"University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK"},{"name":"NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK"},{"name":"NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-7701","authenticated-orcid":false,"given":"Frederique","family":"Ponchel","sequence":"additional","affiliation":[{"name":"University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2021080220105194300_keaa817-B1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial Spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"year":"2013","key":"2021080220105194300_keaa817-B2"},{"key":"2021080220105194300_keaa817-B3","first-page":"5324170","article-title":"Disease-modifying effects of long-term and continuous use of nonsteroidal anti-inflammatory drugs (NSAIDs) in spondyloarthritis","volume":"2019","author":"Wong","year":"2019","journal-title":"Adv Pharmacol Sci"},{"key":"2021080220105194300_keaa817-B4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fmed.2019.00214","article-title":"Non-steroidal anti-inflammatory drugs are unlikely to inhibit radiographic progression of ankylosing spondylitis: a systematic review","volume":"6","author":"Zhang","year":"2019","journal-title":"Front Med (Laussane)"},{"key":"2021080220105194300_keaa817-B5","first-page":"CD005468","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","volume":"4","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2021080220105194300_keaa817-B6","doi-asserted-by":"crossref","first-page":"rkz012","DOI":"10.1093\/rap\/rkz012","article-title":"Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis","volume":"3","author":"Yahya","year":"2019","journal-title":"Rheumatol Adv Pract"},{"journal-title":"Arthritis Care Res (Hoboken)","article-title":"Factors predictive of radiographic progression in ankylosing spondylitis","author":"Sari","key":"2021080220105194300_keaa817-B7"},{"key":"2021080220105194300_keaa817-B8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","article-title":"Interferons \u03b1 and \u03b2 as immune regulators\u2014a new look","volume":"14","author":"Biron","year":"2001","journal-title":"Immunity"},{"key":"2021080220105194300_keaa817-B9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/cr.2016.149","article-title":"Innate immune signaling and regulation in cancer immunotherapy","volume":"27","author":"Corrales","year":"2016","journal-title":"Cell Res"},{"key":"2021080220105194300_keaa817-B10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.pathol.3.121806.151449","article-title":"Graft vascular disease: immune response meets the vessel wall","volume":"4","author":"Mitchell","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"2021080220105194300_keaa817-B11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"2021080220105194300_keaa817-B12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2021080220105194300_keaa817-B13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B14","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"2021080220105194300_keaa817-B15","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021080220105194300_keaa817-B16","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/art.38318","article-title":"Reverse interferon signature is characteristic of antigen-presenting cells in human and rat spondyloarthritis","volume":"66","author":"Fert","year":"2014","journal-title":"Arthritis Rheum"},{"key":"2021080220105194300_keaa817-B17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/icb.2012.12","article-title":"Interferon signatures in immune disorders and disease","volume":"90","author":"Forster","year":"2012","journal-title":"Immunol Cell Biol"},{"key":"2021080220105194300_keaa817-B18","first-page":"2798","article-title":"Genome wide gene expression analysis of macrophages from ankylosing spondylitis patients under interferon-gamma treatment","volume":"17","author":"Ma","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2021080220105194300_keaa817-B19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jaut.2010.06.012","article-title":"Activation of the type I interferon pathway in primary Sjogren's syndrome","volume":"35","author":"Mavragani","year":"2010","journal-title":"J Autoimmun"},{"key":"2021080220105194300_keaa817-B20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fimmu.2014.00306","article-title":"Type I interferon in human autoimmunity","volume":"5","author":"Niewold","year":"2014","journal-title":"Front Immunol"},{"key":"2021080220105194300_keaa817-B21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/tpj.2013.48","article-title":"Gene expression analysis in RA: towards personalized medicine","volume":"14","author":"Burska","year":"2014","journal-title":"Pharmacogenomics J"},{"key":"2021080220105194300_keaa817-B22","doi-asserted-by":"crossref","first-page":"e0128262","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PLoS One"},{"key":"2021080220105194300_keaa817-B23","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2009.111690","article-title":"Gene expression profiling reveals a downregulation in immune-associated genes in patients with AS","volume":"69","author":"Duan","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B24","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B25","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1002\/art.24557","article-title":"Neutralization of interferon-\u03b1\/\u03b2-inducible genes and downstream effect in a phase I trial of an anti-interferon-\u03b1 monoclonal antibody in systemic lupus erythematosus","volume":"60","author":"Yao","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021080220105194300_keaa817-B26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/rheumatology\/keu299","article-title":"Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy","volume":"54","author":"Wright","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021080220105194300_keaa817-B27","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s40265-018-0971-x","article-title":"Beyond the TNF-\u03b1 inhibitors: new and emerging targeted therapies for patients with axial spondyloarthritis and their relation to pathophysiology","volume":"74","author":"Pedersen","year":"2018","journal-title":"Drugs"},{"key":"2021080220105194300_keaa817-B28","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/ard.2004.022582","article-title":"Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study","volume":"64","author":"Marzo-Ortega","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B29","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","article-title":"Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study","volume":"44","author":"Marzo-Ortega","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021080220105194300_keaa817-B30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1136\/ard.2009.121327","article-title":"Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis","volume":"69","author":"Barkham","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B31","first-page":"946","article-title":"Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis","volume":"60","author":"Barkham","year":"2009","journal-title":"Ann Rheum Dis"},{"volume-title":"TaqMan\u00ae array plates","year":"2011","key":"2021080220105194300_keaa817-B32"},{"key":"2021080220105194300_keaa817-B33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00109-017-1515-7","article-title":"Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options","volume":"95","author":"Strau\u00df","year":"2017","journal-title":"J Mol Med (Berl)"},{"key":"2021080220105194300_keaa817-B34","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A type I interferon signature in monocytes is associated with poor response to interferon-\u03b2 in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"key":"2021080220105194300_keaa817-B35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sjorgren\u2019s syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B36","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1136\/annrheumdis-2016-210485","article-title":"Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use","volume":"75","author":"van den Hoogen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B37","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysciosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"2021080220105194300_keaa817-B39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ejcb.2011.09.010","article-title":"Interleukin-6 signalling: more than Jaks and STATs","volume":"91","author":"Eulenfeld","year":"2012","journal-title":"Eur J Cell Biol"},{"key":"2021080220105194300_keaa817-B40","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1136\/annrheumdis-2016-209275","article-title":"Evidence of response to IL6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis","volume":"75","author":"Merashli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","article-title":"Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021080220105194300_keaa817-B42","first-page":"17362","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"2021080220105194300_keaa817-B43","doi-asserted-by":"crossref","first-page":"e96053","DOI":"10.1371\/journal.pone.0096053","article-title":"Synthesis of IL-6 by hepatocytes is a normal response to common hepatic stimuli","volume":"9","author":"Norris","year":"2014","journal-title":"PLoS One"},{"key":"2021080220105194300_keaa817-B44","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1067\/mai.2003.108","article-title":"Cytokines and chemokines","volume":"111","author":"Borish","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"2021080220105194300_keaa817-B45","doi-asserted-by":"crossref","first-page":"e1005973","DOI":"10.1371\/journal.ppat.1005973","article-title":"IL-1\u03b2\/IL-6\/CRP and IL-18\/ferritin: distinct inflammatory programs in infections","volume":"12","author":"Slaats","year":"2016","journal-title":"PLoS Pathol"},{"key":"2021080220105194300_keaa817-B46","doi-asserted-by":"crossref","first-page":"545493","DOI":"10.1155\/2014\/545493","article-title":"Cytokines as biomarkers in rheumatoid arthritis","volume":"2014","author":"Burska","year":"2014","journal-title":"Mediators Inflamm"},{"key":"2021080220105194300_keaa817-B47","doi-asserted-by":"crossref","first-page":"a016295","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2021080220105194300_keaa817-B48","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.38628","article-title":"Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures","volume":"66","author":"Chiche","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021080220105194300_keaa817-B49","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3607\/39543709\/keaa817.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/8\/3607\/39543709\/keaa817.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:36:00Z","timestamp":1627936560000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/8\/3607\/6061532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,1,4]]},"published-print":{"date-parts":[[2021,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa817","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"type":"print","value":"1462-0324"},{"type":"electronic","value":"1462-0332"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,4]]}}}